Welcome to our dedicated page for Gossamer Bio news (Ticker: GOSS), a resource for investors and traders seeking the latest updates and insights on Gossamer Bio stock.
Gossamer Bio, Inc. (GOSS) is a clinical-stage biopharmaceutical company advancing novel therapies for immunological, inflammatory, and oncological conditions with significant unmet needs. This dedicated news hub provides investors and industry professionals with essential updates on therapeutic developments, strategic partnerships, and clinical progress.
Access timely announcements including clinical trial milestones, regulatory submissions, and research collaborations. Our curated collection ensures you stay informed about pipeline candidates targeting complex conditions like pulmonary arterial hypertension and inflammatory bowel diseases.
Bookmark this page for centralized access to Gossamer Bio's latest press releases and financial communications. Regularly updated with verified information, this resource supports informed decision-making without speculative commentary.
Gossamer Bio (NASDAQ: GOSS), a late-stage clinical biopharmaceutical company, will release its first quarter 2025 financial results on Thursday, May 15, 2025. The company, which focuses on developing seralutinib for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), will host a conference call and webcast at 4:30 p.m. ET on the same day. Management will discuss financial results and provide a corporate update during the call.
Gossamer Bio (GOSS) has granted stock options to three non-executive employees under its 2023 Employment Inducement Incentive Award Plan. The Compensation Committee approved options to purchase up to 258,750 shares at an exercise price of $1.25 per share, matching GOSS's closing price on May 5, 2025. The options have a 10-year term and will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months, contingent on continued employment. The grants were made as employment inducements in accordance with Nasdaq Listing Rule 5635(c)(4).
Gossamer Bio (NASDAQ: GOSS) announced its upcoming presentation at the American Thoracic Society (ATS) 2025 International Conference in San Francisco from May 16-21, 2025. The company will present a poster titled "Seralutinib in Pulmonary Arterial Hypertension: Exploring Mechanisms of Reverse Remodeling Versus Vasodilation" on Sunday, May 18th. The presentation focuses on seralutinib, which is being developed in collaboration with the Chiesi Group for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The poster will be available on Gossamer Bio's website after the conference.
Gossamer Bio (Nasdaq: GOSS) has announced the approval of inducement grants under Nasdaq Listing Rule 5635(c)(4). The Compensation Committee of Gossamer's Board of Directors has approved non-qualified stock option awards for one non-executive employee to purchase up to 55,000 shares of common stock under the company's 2023 Employment Inducement Incentive Award Plan.
The options, granted on April 7, 2025, have an exercise price of $0.82 per share, matching the closing price of Gossamer's common stock on Nasdaq Global Select Market. The options feature a ten-year term with a four-year vesting schedule: 25% vesting after one year, followed by the remaining balance vesting in 36 monthly installments, contingent on continued employment.
Gossamer Bio (NASDAQ: GOSS) has reported its Q4 and full-year 2024 financial results, highlighting significant progress in its pulmonary hypertension drug development programs. The company's lead candidate, seralutinib, is advancing with the PROSERA Phase 3 trial in PAH, with topline data expected in Q4 2025.
Key developments include seralutinib receiving Orphan Drug Designation in Japan for PAH treatment and plans to initiate a registrational Phase 3 trial for PH-ILD in H2 2025. The company ended 2024 with $294.5 million in cash and equivalents, expected to fund operations into H1 2027.
Financial highlights for 2024 include: R&D expenses of $138.5 million (vs $135.3M in 2023), G&A expenses of $36.1 million (vs $38.5M in 2023), and a significantly reduced net loss of $56.5 million or $0.25 per share (compared to $179.8M or $1.18 per share in 2023).
Gossamer Bio (Nasdaq: GOSS) has announced the approval of inducement grants to five non-executive employees under its 2023 Employment Inducement Incentive Award Plan. The Compensation Committee approved non-qualified stock option awards to purchase up to 342,250 shares of common stock, effective March 5, 2025.
The options were granted at an exercise price of $1.18 per share, matching the closing price of Gossamer's common stock on March 5, 2025. These ten-year term options will vest over four years, with 25% vesting on the one-year anniversary and the remaining balance vesting in 36 monthly installments, contingent on continued employment.
Gossamer Bio (NASDAQ: GOSS) has announced the approval of inducement grants under its 2023 Employment Inducement Incentive Award Plan. The Compensation Committee approved non-qualified stock options for three non-executive employees to purchase up to 510,000 shares of common stock, effective February 5, 2025.
The options have an exercise price of $1.15 per share, matching the closing price of Gossamer's stock on February 5, 2025. These ten-year options will vest over four years, with 25% vesting after one year and the remaining balance vesting in 36 monthly installments, contingent on continued employment. The grants were made as employment inducements in accordance with Nasdaq Listing Rule 5635(c)(4).
FAQ
What is the current stock price of Gossamer Bio (GOSS)?
What is the market cap of Gossamer Bio (GOSS)?
